Overview A Study of Telitacicept in Patients With Primary IgA Nephropathy Status: Not yet recruiting Trial end date: 2025-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy. Phase: Phase 3 Details Lead Sponsor: RemeGen Co., Ltd.